Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Eton Pharmaceuticals to post earnings of $0.05 per share and revenue of $14.33 million for the quarter.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Eton Pharmaceuticals Stock Down 1.5 %
Shares of NASDAQ ETON traded down $0.26 during midday trading on Monday, hitting $17.09. The stock had a trading volume of 154,991 shares, compared to its average volume of 181,098. The stock has a 50 day simple moving average of $14.28 and a 200-day simple moving average of $13.32. The company has a market capitalization of $458.19 million, a PE ratio of -77.66 and a beta of 1.22. Eton Pharmaceuticals has a 1 year low of $3.18 and a 1 year high of $18.41.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. B. Riley reissued a "buy" rating and issued a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Finally, Craig Hallum upped their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, March 19th.
View Our Latest Research Report on Eton Pharmaceuticals
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
See Also
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
